Skip to content
10-Q

Quarterly Report

Dare Bioscience, Inc. DARE

0001401914-26-000026

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 14.98M sh
Shares Diluted Q1 2026 · Mar 31, 2026 14.52M sh
Shares Diluted Q1 2026 · Mar 31, 2025 8.76M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $157.33K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$5.52M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$5.47M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $18.52M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $24.71M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $10.33M
Stockholders Equity Q1 2026 · Mar 31, 2026 $734.45K
Stockholders Equity Q1 2026 · Dec 31, 2025 $2.84M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$9.56M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$6.01M
Current Liabilities Q1 2026 · Mar 31, 2026 $21.12M
Current Liabilities Q1 2026 · Dec 31, 2025 $23.69M
Total Liabilities Q1 2026 · Mar 31, 2026 $27.09M
Total Liabilities Q1 2026 · Dec 31, 2025 $29.63M
Current Assets Q1 2026 · Mar 31, 2026 $21.66M
Current Assets Q1 2026 · Dec 31, 2025 $27.06M
Total Assets Q1 2026 · Mar 31, 2026 $27.83M
Total Assets Q1 2026 · Dec 31, 2025 $32.47M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.21
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.50
Eps Basic Q1 2026 · Mar 31, 2026 −$0.21
Eps Basic Q1 2026 · Mar 31, 2025 −$0.50
Sga Expense Q1 2026 · Mar 31, 2026 $2.25M
Sga Expense Q1 2026 · Mar 31, 2025 $2.31M
Rd Expense Q1 2026 · Mar 31, 2026 $660.46K
Rd Expense Q1 2026 · Mar 31, 2025 $2.3M
Net Income Q1 2026 · Mar 31, 2026 −$3M
Net Income Q1 2026 · Mar 31, 2025 −$4.38M
Operating Income Q1 2026 · Mar 31, 2026 −$3M
Operating Income Q1 2026 · Mar 31, 2025 −$4.58M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $242.33K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $0
Revenue Q1 2026 · Mar 31, 2026 $152.46K
Revenue Q1 2026 · Mar 31, 2025 $25.43K